Henry Kaplan from University of Louisville School of Medicine: Combatting Retinal Degeneration with Glucose

Video

According to Henry Kaplan, MD, University of Louisville School of Medicine, "One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision."

At the ARVO 2016 meeting in Seattle, WA, Henry Kaplan, MD, University of Louisville School of Medicine, discussed how access to glucose that would normally be transplanted to the subretinal space for metabolism could aid in restoring normal rod function in retinal degeneration.

"One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision," Kaplan commented.

Recent Videos
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
© 2024 MJH Life Sciences

All rights reserved.